



Research Note



GlaxoSmithKline

GlaxoSmithKline (“Glaxo”) is one of the world’s leading pharmaceutical research companies. It is regarded as being a defensive company as an increasingly ageing population will need its products, enabling Glaxo to generate cash almost no matter what the economic conditions.

History

Glaxo’s roots go back to the early eighteenth century, evolving out of the British, New Zealand and U.S. companies; Beecham, SmithKline, Glaxo and Wellcome. The company in its present form was formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000.

Operations

Headquartered in the UK and with operations based in the US (which produces 45% of revenues), Glaxo is the largest pharmaceutical company in Europe and a global player with an estimated 7% of the world’s pharmaceutical market. Glaxo employs approximately 99,000 people in over 100 countries, including over 40,000 sales representatives, which makes it an attractive partner for other players seeking to maximise the sales potential of their new drugs.

Research

Over 15,000 people are employed in research to discover new medicines. Of all the global pharmaceuticals Glaxo, with its broad pipeline of drugs under development, is one of the best positioned to handle the current environment of expiring patents on existing drugs.

The company has developed a “drug discovery” organisation, where the pharmaceutical giant attempts to replicate the research and development ethos in much smaller biotech companies in order to find new drugs. It has deliberately shunned large-scale mergers and acquisitions.

Professional partnerships with others in industry, academia and government are another source of research. For example, Glaxo has developed more than 800 early discovery research collaborations with colleges and universities around the globe and they fund research for hundreds of masters-level, doctoral and fellowship students each year.

Strategy

The pharmaceutical industry is experiencing a time of unprecedented challenge. Patent protections coming to an end (which may not be replaced by products of equivalent financial size), regulatory issues and increased pressures from healthcare providers (no longer do pharmaceuticals have to discover and develop-they now have to justify that their products represent the greatest value) have combined to create a difficult environment in which to operate.

In 2008, Glaxo established the following three strategic priorities with the aim of increasing growth, reducing risk and improving long-term financial performance:

1. Grow a diversified global business

Glaxo is reducing risk by broadening and balancing their portfolio, diversifying into new product areas that show potential, whilst fully capturing opportunities for its products across all geographic boundaries.

Future sales growth is to be generated by strengthening the core pharmaceuticals business and supplementing it with increased investment in growth areas such as vaccines, biopharmaceuticals and consumer healthcare.


The group is also investing heavily in emerging markets, a major source of growth for the company.

2. Deliver more products of value

Glaxo is striving to build one of the strongest pipelines in the industry. The Research & Development department is being transformed to ensure that they not only deliver the current pipeline but are also able to sustain a flow of new products for years to come.

As Glaxo moves towards a more diversified business it will concentrate on developing a higher volume of mid-size products for more clearly defined patient populations. This will help develop a lower risk portfolio, which is not dependent on the performance of one or two large products.

There are currently 30 late-stage assets in the pharmaceuticals and vaccines pipeline and the objective is to sustain this throughput of products over the long-term.



3. Simplify Glaxos's operating model

Glaxo is a complex organisation and management recognises the need to simplify their operating model further, changing the way they work and removing unnecessary processes and structures, which slow them down.

The global restructuring programme is a vital catalyst of this strategy, aimed at radically changing it's business model to give them the capability to support a more diverse, growing business that is also expected to be more profitable in the long term.

Products

1. Prescription Medicines

Glaxo produces medicines that treat six major disease areas – asthma, virus control, infections, mental health, diabetes and digestive conditions.

They are one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization's three priority diseases – HIV/AIDS, tuberculosis and malaria.

2. Vaccines

Glaxo is one of the world's key players in vaccines with their sales generating close to 20% of the global market. They market over 25 vaccines that prevent life-threatening or crippling illnesses such as hepatitis A, B & C, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. Their products are so-called biologics, which are shielded from generic competition because they are so difficult to copy. Glaxo is also targeting therapeutic vaccines that may prevent relapse in cancer patients. The strength of the vaccine pipeline is expected to provide opportunities to consistently deliver new vaccines for many years to come.

3. Consumer Healthcare

The consumer healthcare business brings an added dynamic dimension to the company, yet the driving force behind the business is still science. With four dedicated consumer healthcare R&D centres, the business takes scientific innovation as seriously as it does marketing excellence, as the following products can testify:



Aquafresh

Beechams

Corsodyl

Ribena



Poligrup Ultra



Sensodyne



Horlicks



Panadol

Lucozade

Macleans

Nicorette

In contrast to the more volatile nature of the pharmaceutical markets, the Consumer Healthcare business offers long-term steady cash flow which can help mitigate the impact of losses to generics. The business also capitalises on the growing trend worldwide for patients to manage their own healthcare, choosing OTC products, rather than relying on a prescription.

21 July 2009

Research Disclaimer:

Gibraltar Asset Management Limited is a member firm of the London Stock Exchange and is authorised and regulated by the Gibraltar Financial Services Commission. Research: Neither the information nor the expressed opinions in this document constitute or intend to be an offer, or a solicitation of an offer, to buy or sell relevant securities (i.e. securities mentioned herein and options, warrants, or rights to or interests in any such securities). The information and opinions contained in this document have been compiled from, and based upon generally available information and independent research undertaken by ourselves or by our team of London based institutional analysts, which has been qualified and reviewed by our portfolio managers for suitability. However, the accuracy or completeness of the analysis cannot be guaranteed. Confidentiality: The information in this document and any attachments may contain proprietary information some or all of which may be legally privileged. It must not be disclosed to or used by persons other than the intended recipient. If received in error, please notify us immediately and then delete this document. Content: Please note that the content of this document may be e-mailed and may be intercepted, monitored or recorded for compliance purposes. Copyright: Copyright in this document and any attachments created by Gibraltar Asset Management Limited belongs to Gibraltar Asset Management Limited unless otherwise stated. Care: Gibraltar Asset Management Limited shall not be liable to the recipient or any third party for any loss or damage howsoever arising from this document and / or its content, including if e-mailed, loss or damage caused by virus. It is the responsibility of the recipient to ensure that the opening or use of this document and any attachments shall not adversely affect systems or data. Contact: Telephone 00350 200 75181 Mail: gam@gam.gi Website:www.gam.gi